Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

5BUE

ERK2 complexed with N-benzylpyridone tetrahydroazaindazole

Summary for 5BUE
Entry DOI10.2210/pdb5bue/pdb
Related1ERK 5BUI 5BUJ
DescriptorMitogen-activated protein kinase 1, 1-benzyl-4-[3-(pyridin-4-yl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]pyridin-2(1H)-one, NICKEL (II) ION, ... (4 entities in total)
Functional Keywordserk kinase, atp inhibitor, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceHomo sapiens (Human)
Cellular locationCytoplasm, cytoskeleton, spindle : P28482
Total number of polymer chains1
Total formula weight41909.76
Authors
Bellamacina, C.R.,Shu, W.,Bussiere, D.E.,Bagdanoff, J.T. (deposition date: 2015-06-03, release date: 2015-07-15, Last modification date: 2024-03-06)
Primary citationBagdanoff, J.T.,Jain, R.,Han, W.,Poon, D.,Lee, P.S.,Bellamacina, C.,Lindvall, M.
Ligand efficient tetrahydro-pyrazolopyridines as inhibitors of ERK2 kinase.
Bioorg.Med.Chem.Lett., 25:3626-3629, 2015
Cited by
PubMed Abstract: A series of structure based drug design hypotheses and focused screening efforts drove improvements in the potency and lipophilic efficiency of tetrahydro-pyrazolopyridine based ERK2 inhibitors. Elaboration of a fragment chemical lead established a new lipophilic aryl-Tyr interaction resulting in a substantial potency improvement. Subsequent cleavage of the lipophilic moiety led to reconfiguration of the ligand bound binding cleft. The reconfiguration established a polar contact between a newly liberated N-H and a vicinal Asp, resulting in further improvements in lipophilic efficiency and in vitro clearance.
PubMed: 26144345
DOI: 10.1016/j.bmcl.2015.06.063
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.4 Å)
Structure validation

227111

PDB entries from 2024-11-06

PDB statisticsPDBj update infoContact PDBjnumon